CAR-T新型联用策略治疗实体瘤研究进展

Research progress of CAR-T immunotherapy in solid tumors combined with new strategies

近年来,嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在血液肿瘤的治疗中取得了突破性进展,但是在实体瘤的治疗中仍然存在着诸多问题,例如CAR-T细胞渗透性差,易发生T细胞耗竭现象、脱靶效应等,故实体瘤的CAR-T疗法需要提出新的治疗策略来提升治疗效果。与单一CAR-T治疗方式相比,CAR-T联合其他肿瘤治疗手段已经在临床前及临床研究中展现出优异疗效。本篇综述总结了CAR-T联用不同肿瘤治疗方法:抗体药物、溶瘤病毒、肿瘤疫苗、纳米药物应对实体瘤治疗的研究进展,以期为开发新的CAR-T联用策略治疗实体瘤提供理论依据和新思路。

In recent years,the chimeric antigen receptor T-cell(CAR-T)therapy has achieved breakthrough progress in the treatment of hematologic malignancies.However,when it comes to solid tumors,numerous chal⁃lenges persist.These include limited CAR-T cell infiltration,susceptibility to T cell exhaustion,off-target effects,and more.Thus,novel therapeutic strategies are imperative to enhance the efficacy of CAR-T therapy for solid tumors.In comparison to standalone CAR-T approaches,the combination of CAR-T with other tumor treat⁃ment modalities has demonstrated remarkable effectiveness in both preclinical and clinical research.This review article summarizes the advancements in combining CAR-T with various solid tumor treatments:antibody drugs,oncolytic viruses,tumor vaccines,and nanomedicines.The objective is to furnish a theoretical foundation and novel perspectives for the development of innovative CAR-T combination strategies tailored for solid tumor therapy.